Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Abstract The combination of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Currently, there are no robust biomarkers t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-08-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-023-00574-7 |
| _version_ | 1797557578959421440 |
|---|---|
| author | Mohammadhadi Khorrami Vidya Sakar Viswanathan Priyanka Reddy Nathaniel Braman Siddharth Kunte Amit Gupta Jame Abraham Alberto J. Montero Anant Madabhushi |
| author_facet | Mohammadhadi Khorrami Vidya Sakar Viswanathan Priyanka Reddy Nathaniel Braman Siddharth Kunte Amit Gupta Jame Abraham Alberto J. Montero Anant Madabhushi |
| author_sort | Mohammadhadi Khorrami |
| collection | DOAJ |
| description | Abstract The combination of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Currently, there are no robust biomarkers that can predict response to CDK4/6i, and it is not clear which patients benefit from this therapy. Since MBC patients with liver metastases have a poorer prognosis, developing predictive biomarkers that could identify patients likely to respond to CDK4/6i is clinically important. Here we show the ability of imaging texture biomarkers before and a few cycles after CDK4/6i therapy, to predict early response and overall survival (OS) on 73 MBC patients with known liver metastases who received palbociclib plus ET from two sites. The delta radiomic model was associated with OS in validation set (HR: 2.4; 95% CI, 1.06–5.6; P = 0.035; C-index = 0.77). Compared to RECIST response, delta radiomic features predicted response with area under the curve (AUC) = 0.72, 95% confidence interval (CI) 0.67–0.88. Our study revealed that radiomics features can predict a lack of response earlier than standard anatomic/RECIST 1.1 assessment and warrants further study and clinical validation. |
| first_indexed | 2024-03-10T17:18:47Z |
| format | Article |
| id | doaj.art-f997f48cfd63439786061cd76e2b42ae |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-10T17:18:47Z |
| publishDate | 2023-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-f997f48cfd63439786061cd76e2b42ae2023-11-20T10:25:29ZengNature Portfolionpj Breast Cancer2374-46772023-08-01911910.1038/s41523-023-00574-7Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancerMohammadhadi Khorrami0Vidya Sakar Viswanathan1Priyanka Reddy2Nathaniel Braman3Siddharth Kunte4Amit Gupta5Jame Abraham6Alberto J. Montero7Anant Madabhushi8Department of Biomedical Engineering, Emory UniversityDepartment of Biomedical Engineering, Emory UniversityDepartment of Medicine, Division of Hematology and Oncology, University Hospitals/Seidman Cancer Center, Case Western Reserve UniversityDepartment of Biomedical Engineering, Case Western Reserve UniversityTaussig Cancer Institute, Cleveland ClinicDepartment of Medicine, Division of Hematology and Oncology, University Hospitals/Seidman Cancer Center, Case Western Reserve UniversityTaussig Cancer Institute, Cleveland ClinicDepartment of Medicine, Division of Hematology and Oncology, University Hospitals/Seidman Cancer Center, Case Western Reserve UniversityDepartment of Biomedical Engineering, Emory UniversityAbstract The combination of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Currently, there are no robust biomarkers that can predict response to CDK4/6i, and it is not clear which patients benefit from this therapy. Since MBC patients with liver metastases have a poorer prognosis, developing predictive biomarkers that could identify patients likely to respond to CDK4/6i is clinically important. Here we show the ability of imaging texture biomarkers before and a few cycles after CDK4/6i therapy, to predict early response and overall survival (OS) on 73 MBC patients with known liver metastases who received palbociclib plus ET from two sites. The delta radiomic model was associated with OS in validation set (HR: 2.4; 95% CI, 1.06–5.6; P = 0.035; C-index = 0.77). Compared to RECIST response, delta radiomic features predicted response with area under the curve (AUC) = 0.72, 95% confidence interval (CI) 0.67–0.88. Our study revealed that radiomics features can predict a lack of response earlier than standard anatomic/RECIST 1.1 assessment and warrants further study and clinical validation.https://doi.org/10.1038/s41523-023-00574-7 |
| spellingShingle | Mohammadhadi Khorrami Vidya Sakar Viswanathan Priyanka Reddy Nathaniel Braman Siddharth Kunte Amit Gupta Jame Abraham Alberto J. Montero Anant Madabhushi Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer npj Breast Cancer |
| title | Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer |
| title_full | Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer |
| title_fullStr | Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer |
| title_full_unstemmed | Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer |
| title_short | Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer |
| title_sort | radiomic predicts early response to cdk4 6 inhibitors in hormone receptor positive metastatic breast cancer |
| url | https://doi.org/10.1038/s41523-023-00574-7 |
| work_keys_str_mv | AT mohammadhadikhorrami radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT vidyasakarviswanathan radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT priyankareddy radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT nathanielbraman radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT siddharthkunte radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT amitgupta radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT jameabraham radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT albertojmontero radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer AT anantmadabhushi radiomicpredictsearlyresponsetocdk46inhibitorsinhormonereceptorpositivemetastaticbreastcancer |